Skye Bioscience Class Action Launched, Lead Plaintiff Deadline January 16
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Globenewswire
- Class Action Notification: Rosen Law Firm reminds investors who purchased Skye Bioscience securities between November 4, 2024, and October 3, 2025, that the lead plaintiff deadline is January 16, 2026, potentially allowing for compensation without out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Skye made materially false and misleading statements regarding its product nimacimab, resulting in investor losses when the true information was revealed, indicating a significant trust crisis for the company in the market.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, showcasing its successful track record and resource advantages in handling such cases.
- Investor Advice: Investors are advised to select counsel with a proven track record to ensure optimal representation in class actions, avoiding firms that merely act as intermediaries without litigation experience.
Analyst Views on SKYE
Wall Street analysts forecast SKYE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKYE is 9.80 USD with a low forecast of 2.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.050
Low
2.00
Averages
9.80
High
20.00
Current: 1.050
Low
2.00
Averages
9.80
High
20.00
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
